Acurx Pharmaceuticals Files S-1 Registration
Ticker: ACXP · Form: S-1 · Filed: Apr 4, 2025 · CIK: 1736243
| Field | Detail |
|---|---|
| Company | Acurx Pharmaceuticals, Inc. (ACXP) |
| Form Type | S-1 |
| Filed Date | Apr 4, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, s-1, pharmaceuticals, ipo-readiness
TL;DR
Acurx Pharma filed an S-1, looks like they're raising capital soon.
AI Summary
Acurx Pharmaceuticals, Inc. filed an S-1 registration statement on April 4, 2025, to register securities under the Securities Act of 1933. The company, incorporated in Delaware with its principal executive offices at 259 Liberty Avenue, Staten Island, NY, operates in the Pharmaceutical Preparations sector. David P. Luci serves as President and Chief Executive Officer.
Why It Matters
This S-1 filing indicates Acurx Pharmaceuticals is preparing to offer securities to the public, which could lead to significant capital infusion for its operations or expansion.
Risk Assessment
Risk Level: medium — S-1 filings are typically associated with new public offerings, which carry inherent market and execution risks for the company and investors.
Key Numbers
- 333-286384 — SEC File Number (Identifies this specific registration statement)
- 0001736243 — Central Index Key (Unique identifier for the company in SEC filings)
Key Players & Entities
- Acurx Pharmaceuticals, Inc. (company) — Registrant
- David P. Luci (person) — President and Chief Executive Officer
- 259 Liberty Avenue Staten Island, New York 10305 (location) — Principal Executive Offices
- April 4, 2025 (date) — Filing Date
- Securities Act of 1933 (legal_document) — Governing Act
FAQ
What is the purpose of this S-1 filing?
The S-1 filing is a registration statement under the Securities Act of 1933, indicating Acurx Pharmaceuticals, Inc. is preparing to offer securities to the public.
When was this S-1 filing submitted?
The S-1 filing was submitted to the SEC on April 4, 2025.
Who is the President and CEO of Acurx Pharmaceuticals?
David P. Luci is the President and Chief Executive Officer of Acurx Pharmaceuticals, Inc.
What is the primary business sector of Acurx Pharmaceuticals?
Acurx Pharmaceuticals, Inc. operates in the Pharmaceutical Preparations sector, with a Standard Industrial Classification code of 2834.
Where are Acurx Pharmaceuticals' principal executive offices located?
The principal executive offices of Acurx Pharmaceuticals are located at 259 Liberty Avenue, Staten Island, New York 10305.
Filing Details
This Form S-1 (Form S-1) was filed with the SEC on April 4, 2025 by David P. Luci regarding Acurx Pharmaceuticals, Inc. (ACXP).